tiprankstipranks
Trending News
More News >

SanBio Reports Increased Losses in Q1 2025 Amid Strategic Focus

Story Highlights
SanBio Reports Increased Losses in Q1 2025 Amid Strategic Focus

Elevate Your Investing Strategy:

SanBio Co ( (JP:4592) ) has shared an announcement.

SanBio Company Limited reported its consolidated financial results for the three months ended April 30, 2025, showing a net loss of ¥1,531 million, a significant increase from the previous year’s loss of ¥144 million. The company’s financial position showed an increase in total assets but a decrease in equity ratio, indicating potential challenges in financial stability. Despite these losses, SanBio continues to focus on its long-term strategic goals in the biotechnology sector.

The most recent analyst rating on (JP:4592) stock is a Hold with a Yen1400.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.

More about SanBio Co

SanBio Company Limited is a biotechnology company listed on the Tokyo Stock Exchange, focusing on regenerative cell therapies. The company is involved in developing innovative treatments aimed at addressing unmet medical needs, primarily in the field of neurological disorders.

Average Trading Volume: 5,613,796

Technical Sentiment Signal: Buy

Current Market Cap: Yen265B

Learn more about 4592 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1